ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PHAT vs INDP // 10Y YIELD & FRED MACRO BETA

Phathom Pharmaceuticals Inc. (NASDAQ) VS. Indaptus Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PHAT 1 — INDP 2
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAT VS. INDP) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PHAT INDP SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — -2.89% — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -0.10% — — TIE /net-margins <GO>
Revenue Growth (YoY) 180.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 PHAT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 36.7 53.2 -16.50 INDP /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $466.6M $474.6M -$8.0M INDP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PHAT REV INDP REV PHAT GROSS % INDP GROSS % PHAT FCF INDP FCF
FY 2025 $175.1M $55.5M 87.1% — -$167.0M -$14.8M
FY 2024 $55.3M $43.0M 85.6% — -$266.9M -$12.3M
FY 2023 $682.0K $45.9M — — -$137.6M -$13.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAT // BETA —
INDP // BETA —